Accustem Sciences (ACUT) Consolidated Net Income (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Consolidated Net Income of -$485883.0 for Q1 2026, down 10.33% year-over-year from -$541830.5 in Q1 2025, and up 5.54% quarter-over-quarter from -$514388.0 in Q4 2025.
Accustem Sciences (ACUT) Consolidated Net Income (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Consolidated Net Income for 6 consecutive years, with -$485883.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 10.33% year-over-year to -$485883.0; the TTM figure through Mar 2026 stood at -$1.8 million (down 26.97% YoY), while the FY2025 annual figure was -$1.8 million, down 16.68% from the prior year.
- Consolidated Net Income advanced to -$485883.0 in Q1 2026 per ACUT's latest filing, from -$514388.0 in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$246042.0 in Q4 2023 and bottomed at -$1.1 million in Q2 2022.
- Historically, Consolidated Net Income has averaged -$561421.4 across 5 years, with a median of -$485883.0 in 2026.
- Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 5598.36% — and 2023, when it soared 74.86%.
- Accustem Sciences' Consolidated Net Income stood at -$978534.0 in 2022, then jumped by 74.86% to -$246042.0 in 2023, then slumped by 51.23% to -$372101.0 in 2024, then plunged by 38.24% to -$514388.0 in 2025, then advanced by 5.54% to -$485883.0 in 2026.
- Business Quant data shows ACUT's Consolidated Net Income at -$485883.0 in Q1 2026, -$514388.0 in Q4 2025, and -$399897.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | -252,573.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -485,883.00 |
| Dec 31, 2025 | -514,388.00 |
| Sep 30, 2025 | -399,897.00 |
| Jun 30, 2025 | -401,403.00 |
| Mar 31, 2025 | -440,408.00 |
| Dec 31, 2024 | -372,101.00 |
| Sep 30, 2024 | -328,174.00 |
| Jun 30, 2024 | -278,225.00 |
| Mar 31, 2024 | -526,602.00 |
| Dec 31, 2023 | -246,042.00 |
| Sep 30, 2023 | -598,525.00 |
| Jun 30, 2023 | -372,756.00 |
| Mar 31, 2023 | -833,341.00 |
| Dec 31, 2022 | -978,534.00 |
| Sep 30, 2022 | -899,125.00 |
| Jun 30, 2022 | -1.08 Mn |
| Mar 31, 2022 | -790,534.00 |
| Dec 31, 2021 | -543,482.00 |
| Sep 30, 2021 | -62,722.00 |
| Jun 30, 2021 | -50,537.00 |